Neurophysiopathology Unit, Neuromuscolar Department - AOU Careggi, Florence, Italy.
IRCCS Don Carlo Gnocchi, Florence, Italy.
Acta Neurol Scand. 2021 Aug;144(2):161-169. doi: 10.1111/ane.13433. Epub 2021 Apr 22.
Critical illness polyneuropathy and myopathy (CIPNM) is a frequent neurological manifestation in patients with acute respiratory distress syndrome (ARDS) from coronavirus disease 2019 (COVID-19) infection. CIPNM diagnosis is usually limited to clinical evaluation. We compared patients with ARDS from COVID-19 and other aetiologies, in whom a neurophysiological evaluation for the detection of CIPNM was performed. The aim was to determine if there were any differences between these two groups in frequency of CINPM and outcome at discharge from the intensive care unit (ICU).
This was a single-centre retrospective study performed on mechanically ventilated patients consecutively admitted (January 2016-June 2020) to the ICU of Careggi Hospital, Florence, Italy, with ARDS of different aetiologies. Neurophysiological evaluation was performed on patients with stable ventilation parameters, but marked widespread hyposthenia (Medical Research Council score <48). Creatine phosphokinase (CPK), lactic dehydrogenase (LDH) and mean morning glycaemic values were collected.
From a total of 148 patients, 23 with COVID-19 infection and 21 with ARDS due to other aetiologies, underwent electroneurography/electromyography (ENG/EMG) recording. Incidence of CIPNM was similar in the two groups, 65% (15 of 23) in COVID-19 patients and 71% (15 of 21) in patients affected by ARDS of other aetiologies. At ICU discharge, subjects with CIPNM more frequently required ventilatory support, regardless the aetiology of ARDS.
ENG/EMG represents a useful tool in the identification of the neuromuscular causes underlying ventilator wean failure and patient stratification. A high incidence of CIPNM, with a similar percentage, has been observed in ARDS patients of all aetiologies.
危重病性多发性神经病和肌病(CIPNM)是 2019 年冠状病毒病(COVID-19)感染所致急性呼吸窘迫综合征(ARDS)患者常见的神经表现。CIPNM 的诊断通常仅限于临床评估。我们比较了 COVID-19 和其他病因引起的 ARDS 患者,对这些患者进行了神经生理学评估以检测 CIPNM。目的是确定这两组患者 CINPM 的发生率以及从重症监护病房(ICU)出院时的结局是否存在差异。
这是一项单中心回顾性研究,连续纳入(2016 年 1 月至 2020 年 6 月)意大利佛罗伦萨 Careggi 医院 ICU 中患有不同病因 ARDS 的机械通气患者。对通气参数稳定但广泛肌无力(肌容积力量测定法评分<48)明显的患者进行神经生理学评估。收集肌酸磷酸激酶(CPK)、乳酸脱氢酶(LDH)和平均清晨血糖值。
共有 148 例患者,其中 23 例 COVID-19 感染,21 例其他病因 ARDS,进行了神经电图/肌电图(ENG/EMG)记录。两组 CIPNM 的发生率相似,COVID-19 患者为 65%(23/23),其他病因 ARDS 患者为 71%(21/21)。在 ICU 出院时,无论 ARDS 的病因如何,患有 CIPNM 的患者更频繁地需要通气支持。
ENG/EMG 是确定导致呼吸机撤机失败和患者分层的神经肌肉原因的有用工具。所有病因的 ARDS 患者均观察到 CIPNM 的发生率较高,且百分比相似。